Pfizer's Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer
Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating …